Ginkgo Bioworks FY2021 revenue $314M (+309% YoY); 2022 guidance $325-340M

Ginkgo Bioworks Holdings, Inc.

Full-year 2021 total revenue $314M, up 309% YoY; Foundry revenue $113M (+91%), Biosecurity $201M (exceeded $110M outlook).
Added 31 new Cell Programs in 2021 (+72% YoY); 2022 guidance expects 60 new programs.
Q4 2021 total revenue $148M vs $32M YoY; Adjusted EBITDA $1M vs $(51)M in prior year.
GAAP loss from ops $(1.8)B including $1.7B catch-up stock comp; cash balance >$1.5B.
Announced two tuck-in acquisitions in 2022: Project Beacon (COVID testing) and FGen (strain optimization).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.